Details of the Drug Formulations

General Information of Drug (ID: DMS0ZBI)

Drug Name
AG-221 Drug Info
Synonyms AG-221 (IDH2 inhibitor)
Indication
Disease Entry ICD 11 Status REF
Acute myelogenous leukaemia 2A41 Phase 3 [1]
Acute myeloid leukaemia 2A60 Phase 1/2 [2]
Cross-matching ID
PubChem CID
89683805
ChEBI ID
CHEBI:145374
CAS Number
1446502-11-9
TTD ID
D0K7FT
ACDINA ID
D00230

Full List of Drug Formulations Containing This Drug

Enasidenib 100 mg tablet
Company Formulation ID FDA Description
Celgene Corporation F07281 Sodium lauryl sulfate; Magnesium stearate; Ferric oxide yellow; Talc; Titanium dioxide; Polyvinyl alcohol; Silicon dioxide; Hydroxypropyl cellulose, unspecified; Hypromellose acetate succinate 06081224 (3 mm2/s); Microcrystalline cellulose; Polyethylene glycol; Sodium starch glycolate type a potato
------------------------------------------------------------------------------------
Enasidenib 50 mg tablet
Company Formulation ID FDA Description
Celgene Corporation F07282 Sodium lauryl sulfate; Magnesium stearate; Ferric oxide yellow; Talc; Titanium dioxide; Polyvinyl alcohol; Silicon dioxide; Hydroxypropyl cellulose, unspecified; Hypromellose acetate succinate 06081224 (3 mm2/s); Microcrystalline cellulose; Polyethylene glycol; Sodium starch glycolate type a potato
------------------------------------------------------------------------------------
Enasidenib Mesylate 100 mg tablet
Company Formulation ID FDA Description
Celgene Corporation F24311 Colloidal Silicon Dioxide; Hydroxypropyl Cellulose; Hypromellose Acetate Succinate; Iron Oxide Yellow; Magnesium Stearate; Microcrystalline Cellulose; Polyethylene Glycol; Polyvinyl Alcohol; Sodium Lauryl Sulfate; Sodium Starch Glycolate; Talc; Titanium Dioxide
------------------------------------------------------------------------------------
Enasidenib Mesylate 50 mg tablet
Company Formulation ID FDA Description
Celgene Corporation F24393 Colloidal Silicon Dioxide; Hydroxypropyl Cellulose; Hypromellose Acetate Succinate; Iron Oxide Yellow; Magnesium Stearate; Microcrystalline Cellulose; Polyethylene Glycol; Polyvinyl Alcohol; Sodium Lauryl Sulfate; Sodium Starch Glycolate; Talc; Titanium Dioxide
------------------------------------------------------------------------------------

References

1 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
2 ClinicalTrials.gov (NCT02273739) Study of Orally Administered AG-221 in Subjects With Advanced Solid Tumors, Including Glioma, and With Angioimmunoblastic T-cell Lymphoma, With an IDH2 Mutation. U.S.National Institutes of Health.